Ornella Verrastro
Overview
Explore the profile of Ornella Verrastro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angelini G, Panunzi S, Pompili M, Riccardi L, Garcovich M, Verrastro O, et al.
Clin Chem
. 2025 Jan;
71(3):406-417.
PMID: 39786442
Background: Noninvasive tests (NITs) to monitor metabolic dysfunction-associated steatohepatitis (MASH) progression and response to interventions are needed because of the risks of liver biopsy. A monocytes-based diagnostic test using perilipin-2...
2.
Sabatini S, Sen P, Carli F, Pezzica S, Rosso C, Lembo E, et al.
Cell Rep Med
. 2024 Nov;
5(11):101820.
PMID: 39566466
Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with a high prevalence of type 2 diabetes (T2D). Individuals with MASLD exhibit insulin resistance (IR) and hyperglycemia, but...
3.
Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Verrastro O, Axarloglou E, Mylonakis S, et al.
Clin Nutr
. 2024 Oct;
43(12):101-108.
PMID: 39442390
Background & Aims: The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III...
4.
De Maio F, Boru C, Velotti N, Capoccia D, Santarelli G, Verrastro O, et al.
Surg Endosc
. 2024 Sep;
38(11):6643-6656.
PMID: 39294316
Background: Roux-en-Y (RYGB) and one anastomosis gastric bypass (OAGB) represent two of the most used bariatric/metabolic surgery (BMS) procedures. Gut microbiota (GM) shift after bypass surgeries, currently understated, may be...
5.
Kouvari M, Valenzuela-Vallejo L, Axarloglou E, Verrastro O, Papatheodoridis G, Mingrone G, et al.
Liver Int
. 2024 Jan;
44(3):848-864.
PMID: 38263703
Background And Aims: Thyroid axis is currently under investigation as a therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD). Thyroid function was examined herein in the full spectrum of...
6.
Valenzuela-Vallejo L, Chrysafi P, Kouvari M, Guatibonza-Garcia V, Mylonakis S, Katsarou A, et al.
Metabolism
. 2023 Sep;
148:155694.
PMID: 37757973
Background: The role of metabolic/inflammatory hormonal systems in metabolic dysfunction associated steatotic liver disease (MASLD) remains to be fully elucidated. Purpose: To report the levels of the novel total and...
7.
Saux P, Bauvin P, Raverdy V, Teigny J, Verkindt H, Soumphonphakdy T, et al.
Lancet Digit Health
. 2023 Aug;
5(10):e692-e702.
PMID: 37652841
Background: Weight loss trajectories after bariatric surgery vary widely between individuals, and predicting weight loss before the operation remains challenging. We aimed to develop a model using machine learning to...
8.
Kouvari M, Mylonakis S, Katsarou A, Valenzuela-Vallejo L, Guatibonza-Garcia V, Kokkorakis M, et al.
Diabetes Res Clin Pract
. 2023 Aug;
203:110870.
PMID: 37567510
Aims: A new non-invasive tool (NIT) for non-alcoholic fatty liver disease (NAFLD) proposed in 2022 by the multi-ethnic Dallas Heart Study, i.e. the Dallas Steatosis Index (DSI), was validated herein...
9.
Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos S, Deng Y, Kokkorakis M, et al.
Metabolism
. 2023 Aug;
147:155666.
PMID: 37527759
Background: Non-invasive tools (NIT) for metabolic-dysfunction associated liver disease (MASLD) screening or diagnosis need to be thoroughly validated using liver biopsies. Purpose: To externally validate NITs designed to differentiate the...
10.
Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E, et al.
Lancet
. 2023 Apr;
401(10390):1786-1797.
PMID: 37088093
Background: Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle...